Citation Impact
Citing Papers
Hepatitis C Virus Screening Among Children Exposed During Pregnancy
2018
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
2013
Bile acid transporters and regulatory nuclear receptors in the liver and beyond
2012
Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
2017 Standout
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
2012
Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes
2016
Nonalcoholic Fatty Liver Disease: A Novel Cardiometabolic Risk Factor for Type 2 Diabetes and Its Complications
2013
Glucagon‐like peptide‐1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high‐fat diet in nonalcoholic steatohepatitis
2011
Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: A retrospective study
2013
Trends in GPCR drug discovery: new agents, targets and indications
2017 Standout
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension
2014 Standout
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
2016 Standout
Non-alcoholic fatty liver disease
2021 Standout
Leptin Promotes the Myofibroblastic Phenotype in Hepatic Stellate Cells by Activating the Hedgehog Pathway
2010
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
2013 Standout
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
2018 Standout
GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy
2011
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
Therapeutic Landscape for NAFLD in 2020
2020
Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
2014
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
2010
Exendin-4 Improves Steatohepatitis by Increasing Sirt1 Expression in High-Fat Diet-Induced Obese C57BL/6J Mice
2012
NAFLD: A multisystem disease
2015 Standout
Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma
2015
Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic Gluconeogenesis
2011
Hepatocellular carcinoma
2022 Standout
Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis
2017
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program
2012
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
2013
Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in J apanese patients (LEAN ‐J )
2014
Sexually Transmitted Infections Treatment Guidelines, 2021
2021 Standout
Cardiovascular Biology of the Incretin System
2012
Intestinal permeability – a new target for disease prevention and therapy
2014 Standout
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet
2011
Lipotoxicity and the gut-liver axis in NASH pathogenesis
2017
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
2023 Standout
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
2012
Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells
2011
Works of Nitika Gupta being referenced
Adiponectin activation of AMPK disrupts leptin‐mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS‐3)
2010
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling Pathway
2010
NASPGHAN Practice Guidelines
2012